Colleran David 4
4 · Anika Therapeutics, Inc. · Filed Mar 11, 2025
Insider Transaction Report
Form 4
Colleran David
EVP, General Counsel, Corp Sec
Transactions
- Tax Payment
Common Stock
2025-03-10$16.62/sh−1,604$26,658→ 37,986 total - Exercise/Conversion
Restricted Stock Unit
2025-03-10−5,465→ 5,465 totalExercise: $0.00→ Common Stock (5,465 underlying) - Exercise/Conversion
Common Stock
2025-03-10+5,465→ 39,590 total
Footnotes (5)
- [F1]Reflects the second vesting installment of RSUs granted on March 9, 2023.
- [F2]Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 800 shares purchased on May 14, 2024 and 330 shares purchased on November 14, 2024.
- [F3]Reflects an aggregate of 1,604 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2025.
- [F4]Reflects the closing price of ANIK common stock on March 7, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations.
- [F5]Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024.